Mitochondrial disorders: Aetiologies, models systems, and candidate therapies

Trends in Genetics

Volumn 29, Issue 8, 2013, Pages 488-497

  Farrar, G Jane ^a   Chadderton, Naomi ^a   Kenna, Paul F ^a   Millington Ward, Sophia ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Gene therapy; Leber hereditary optic neuropathy; Mitochondrial disease

Indexed keywords

APOPTOSIS INDUCING FACTOR; AROMATIC LEVO AMINO ACID DECARBOXYLASE; DNA DIRECTED DNA POLYMERASE GAMMA; MITOCHONDRIAL DNA; MITOCHONDRIAL RNA; ORNITHINE CARBAMOYLTRANSFERASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; TYROSINE 3 MONOOXYGENASE;

AUTOSOMAL DOMINANT OPTIC ATROPHY; CELL ENERGY; COMPLEX I DEFICIENCY; DIABETIC RETINOPATHY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ELECTRON TRANSPORT; GENE MUTATION; GENE REPLACEMENT THERAPY; HEARING IMPAIRMENT; HUMAN; KEARNS SAYRE SYNDROME; LEBER HEREDITARY OPTIC NEUROPATHY; MELAS SYNDROME; MITOCHONDRIAL GENE; MITOCHONDRIAL MYOPATHY; MITOCHONDRION; NARP SYNDROME; NONHUMAN; ORNITHINE TRANSCARBAMYLASE DEFICIENCY; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; TRANSGENICS;

GENE THERAPY; LEBER HEREDITARY OPTIC NEUROPATHY; MITOCHONDRIAL DISEASE;

ANIMALS; DISEASE MODELS, ANIMAL; DNA, MITOCHONDRIAL; GENETIC THERAPY; HUMANS; MITOCHONDRIA; MUTATION; OPTIC ATROPHY, HEREDITARY, LEBER;

ANIMALIA;

EID: 84880944588     PISSN: 01689525     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tig.2013.05.005     Document Type: Review

References (110)

1. Henze K., Martin W. Evolutionary biology: essence of mitochondria. Nature 2003, 426:127-128.
2. Pearce S., et al. Mitochondrial diseases: translation matters. Mol. Cell. Neurosci. 2012, 55:1-12.
3. Schmitt M.W., et al. Detection of ultra-rare mutations by next-generation sequencing. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:14508-14513.
4. Payne B.A., et al. Universal heteroplasmy of human mitochondrial DNA. Hum. Mol. Genet. 2013, 22:384-390.
5. Ciccone S., et al. Parkinson's disease: a complex interplay of mitochondrial DNA alterations and oxidative stress. Int. J. Mol. Sci. 2013, 14:2388-2409.
6. Smith R.A., et al. Mitochondrial pharmacology. Trends Pharmacol. Sci. 2012, 33:341-352.
7. Karunadharma P.P., et al. Mitochondrial DNA damage as a potential mechanism for age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2010, 51:5470-5479.
8. Hauser D.N., Hastings T.G. Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism. Neurobiol. Dis. 2013, 51:35-42.
9. Maresca A., et al. The optic nerve: a "mito-window" on mitochondrial neurodegeneration. Mol. Cell. Neurosci. 2013, 55:62-76.
10. Yu-Wai-Man P., et al. Pattern of retinal ganglion cell loss in dominant optic atrophy due to OPA1 mutations. Eye 2011, 25:596-602.
11. Newman N.J. Treatment of hereditary optic neuropathies. Nat. Rev. Neurol. 2012, 8:545-556.
12. Barot M., et al. Mitochondrial dysfunction in retinal diseases. Curr. Eye Res. 2011, 36:1069-1077.
13. Duno M., et al. A novel mitochondrial mutation m.8989G>C associated with neuropathy, ataxia, retinitis pigmentosa: the NARP syndrome. Gene 2013, 515:372-375.
14. Comte C., et al. Mitochondrial targeting of recombinant RNAs modulates the level of a heteroplasmic mutation in human mitochondrial DNA associated with Kearns Sayre Syndrome. Nucleic Acids Res. 2013, 41:418-433.
15. Koopman W.J., et al. OXPHOS mutations and neurodegeneration. EMBO J. 2013, 32:9-29.
16. Itoh K., et al. Mitochondrial dynamics in neurodegeneration. Trends Cell Biol. 2013, 23:64-71.
17. Kelly R.D., et al. Mitochondrial DNA copy number is regulated in a tissue specific manner by DNA methylation of the nuclear-encoded DNA polymerase gamma A. Nucleic Acids Res. 2012, 40:10124-10138.
18. Lax N.Z., et al. Sensory neuronopathy in patients harbouring recessive polymerase γ mutations. Brain 2012, 135:62-71.
19. Nicholls T.J., et al. Mitochondria: mitochondrial RNA metabolism and human disease. Int. J. Biochem. Cell Biol. 2013, 45:845-849.
20. Mansergh F.C., et al. Retinitis pigmentosa and progressive sensorineural hearing loss caused by a C12258A mutation in the mitochondrial MTTS2 gene. Am. J. Hum. Genet. 1999, 64:971-985.
21. Goto Y., et al. A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 1990, 348:651-653.
22. Cree L.M., et al. A reduction of mitochondrial DNA molecules during embryogenesis explains the rapid segregation of genotypes. Nat. Genet. 2008, 40:249-254.
23. Tsao K., et al. Smoking as an aetiological factor in a pedigree with Leber hereditary optic neuropathy. Br. J. Ophthalmol. 1999, 83:577-581.
24. Carelli V., et al. Grand rounds: could occupational exposure to n-hexane and other solvents precipitate visual failure in Leber hereditary optic neuropathy?. Environ. Health Perspect. 2007, 115:113-115.
25. Mackey D.A., et al. Leber's hereditary optic neuropathy triggered by antiretroviral therapy for human immunodeficiency virus. Eye 2003, 17:312-317.
26. Shankar S.P., et al. Evidence for a novel x-linked modifier locus for Leber hereditary optic neuropathy. Ophthalmic Genet. 2008, 29:17-24.
27. Butler E.K., et al. The mitochondrial chaperone protein TRAP1 mitigates α-Synuclein toxicity. PLoS Genet. 2012, 8:e1002488.
28. Marcuello A., et al. Human mitochondrial variants influence on oxygen consumption. Mitochondrion 2009, 9:27-30.
29. Hudson G., et al. Clinical expression of Leber hereditary optic neuropathy is affected by the mitochondrial DNA-haplogroup background. Am. J. Hum. Genet. 2007, 81:228-233.
30. Gómez-Durán A., et al. Oxidative phosphorylation differences between mitochondrial DNA haplogroups modify the risk of Leber's hereditary optic neuropathy. Biochim. Biophys. Acta 2012, 1822:1216-1222.
31. Ridge P.G., et al. Mitochondrial genomic analysis of late onset Alzheimer's disease reveals protective haplogroups H6A1A/H6A1B: The Cache County Study on Memory in Aging. PLoS ONE 2012, 7:e45134.
32. Mueller E.E., et al. Mitochondrial haplogroups and control region polymorphisms in age-related macular degeneration: a case-control study. PLoS ONE 2012, 7:e30874.
33. Gómez-Durán A., et al. Unmasking the causes of multifactorial disorders: OXPHOS differences between mitochondrial haplogroups. Hum. Mol. Genet. 2010, 19:3343-3353.
34. Bratic A., Larsson N.G. The role of mitochondria in aging. J. Clin. Invest. 2013, 123:951-957.
35. Trifunovic A., et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 2004, 429:417-423.
36. Trifunovic A., et al. Somatic mtDNA mutations cause aging phenotypes without affecting reactive oxygen species production. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:17993-17998.
37. King M.P., Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 1989, 246:500-503.
38. Ferreira I.L., et al. Bioenergetic dysfunction in Huntington's disease human cybrids. Exp. Neurol. 2011, 231:127-134.
39. Arzuffi P., et al. Partial tandem duplication of mtDNA-tRNA(Phe) impairs mtDNA translation in late-onset mitochondrial myopathy. Neuromuscul. Disord. 2012, 22:50-55.
40. Desquiret-Dumas V., et al. Metabolically induced heteroplasmy shifting and l-arginine treatment reduce the energetic defect in a neuronal-like model of MELAS. Biochim. Biophys. Acta 2012, 1822:1019-1029.
41. Abramov A.Y., et al. Mechanism of neurodegeneration of neurons with mitochondrial DNA mutations. Brain 2010, 133:797-807.
42. Iyer S., et al. Mitochondrial gene replacement in human pluripotent stem cell-derived neural progenitors. Gene Ther. 2012, 19:469-475.
43. Burbulla L.F., et al. Dissecting the role of the mitochondrial chaperone mortalin in Parkinson's disease: functional impact of disease-related variants on mitochondrial homeostasis. Hum. Mol. Genet. 2010, 19:4437-4452.
44. Iyer S., et al. Mitochondrial gene therapy improves respiration, biogenesis, and transcription in G11778A Leber's hereditary optic neuropathy and T8993G Leigh's syndrome cells. Hum. Gene Ther. 2012, 23:647-657.
45. Seibler P., et al. Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 iPS cells. J. Neurosci. 2011, 31:5970-5976.
46. Cooper O., et al. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci. Transl. Med. 2012, 4:141ra90.
47. Tyynismaa H., Suomalainen A. Mouse models of mitochondrial DNA defects and their relevance for human disease. EMBO Rep. 2009, 10:137-143.
48. Quintana A., et al. Complex I deficiency due to loss of Ndufs4 in the brain results in progressive encephalopathy resembling Leigh syndrome. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:10996-11001.
49. Dunn D.A., et al. Animal models of human mitochondrial DNA mutations. Biochim. Biophys. Acta 2012, 1820:601-607.
50. Kujoth G.C., et al. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 2005, 309:481-484.
51. Milenkovic D., et al. TWINKLE is an essential mitochondrial helicase required for synthesis of nascent D-loop strands and complete mtDNA replication. Hum. Mol. Genet. 2013, 22:1983-1993.
52. Dunn D.A., Pinkert C.A. Nuclear expression of a mitochondrial DNA gene: mitochondrial targeting of allotopically expressed mutant ATP6 in transgenic mice. J. Biomed. Biotechnol. 2012, 10.1155/2012/541245.
53. Ellouze S., et al. Optimized allotopic expression of the human mitochondrial ND4 prevents blindness in a rat model of mitochondrial dysfunction. Am. J. Hum. Genet. 2008, 83:373-387.
54. Qi X., et al. The mutant human ND4 subunit of complex I induces optic neuropathy in the mouse. Invest. Ophthalmol. Vis. Sci. 2007, 48:1-10.
55. Cannon M.V., et al. Xenomitochondrial mice: investigation into mitochondrial compensatory mechanisms. Mitochondrion 2011, 11:33-39.
56. Nakada K., Hayashi J. Transmitochondrial mice as models for mitochondrial DNA-based diseases. Exp. Anim. 2011, 60:421-431.
57. Lin C.S., et al. Mouse mtDNA mutant model of Leber hereditary optic neuropathy. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:20065-20070.
58. Shokolenko I.N., et al. The approaches for manipulating mitochondrial proteome. Environ. Mol. Mutagen. 2010, 51:451-461.
59. Heller A., et al. Targeting drugs to mitochondria. Eur. J. Pharm. Biopharm. 2012, 82:1-18.
60. Mileshina D., et al. Mitochondrial transfection for studying organellar DNA repair, genome maintenance and aging. Mech. Ageing Dev. 2011, 132:412-423.
61. Niazi A.K., et al. Targeting nucleic acids into mitochondria: progress and prospects. Mitochondrion 2012, 10.1016/j.mito.2012.05.004.
62. Yasuzaki Y., et al. Mitochondrial matrix delivery using MITO-Porter, a liposome-based carrier that specifies fusion with mitochondrial membranes. Biochem. Biophys. Res. Commun. 2010, 397:181-186.
63. Yamada Y., Harashima H. Enhancement in selective mitochondrial association by direct modification of a mitochondrial targeting signal peptide on a liposomal based nanocarrier. Mitochondrion 2012, 10.1016/j.mito.2012.09.001.
64. Lyrawati D., et al. Expression of GFP in the mitochondrial compartment using DQAsome-mediated delivery of an artificial mini-mitochondrial genome. Pharm. Res. 2011, 28:2848-2862.
65. Smith R.A., Murphy M.P. Mitochondria-targeted antioxidants as therapies. Discov. Med. 2011, 11:106-114.
66. Smith R.A., Murphy M.P. Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann. N. Y. Acad. Sci. 2010, 1201:96-103.
67. Szeto H.H., Schiller P.W. Novel therapies targeting inner mitochondrial membrane: from discovery to clinical development. Pharm. Res. 2011, 28:2669-2679.
68. Keeney P.M., et al. Mitochondrial gene therapy augments mitochondrial physiology in a Parkinson's disease cell model. Hum. Gene Ther. 2009, 20:897-907.
69. Jash S., et al. Modulation of mitochondrial respiratory capacity by carrier-mediated transfer of RNA in vivo. Mitochondrion 2012, 12:262-270.
70. Wang Y., et al. Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Mol. Ther. 2013, 21:358-367.
71. Mercer T.R., et al. The human mitochondrial transcriptome. Cell 2011, 146:645-658.
72. Wang G., et al. Correcting human mitochondrial mutations with targeted RNA import. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:4840-4845.
73. Zimmer K.P., et al. Efficient mitochondrial import of newly synthesized ornithine transcarbamylase (OTC) and correction of secondary metabolic alterations in spf(ash) mice following gene therapy of OTC deficiency. Mol. Med. 1999, 5:244-253.
74. Wang L., et al. Sustained correction of OTC deficiency in spf(ash) mice using optimized self-complementary AAV2/8 vectors. Gene Ther. 2012, 19:404-410.
75. Di, Meo I., et al. Effective AAV-mediated gene therapy in a mouse model of ethylmalonic encephalopathy. EMBO Mol. Med. 2012, 4:1008-1014.
76. Yu H., et al. Gene delivery to mitochondria by targeting modified adenoassociated virus suppresses Leber's hereditary optic neuropathy in a mouse model. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:E1238-E1247.
77. Marella M., et al. Successful amelioration of mitochondrial optic neuropathy using the yeast NDI1 gene in a rat animal model. PLoS ONE 2010, 5:e11472.
78. Chadderton N., et al. Intravitreal delivery of AAV-NDI1 provides functional benefit in a murine model of Leber hereditary optic neuropathy. Eur. J. Hum. Genet. 2013, 21:62-68.
79. Bacman S.R., et al. Manipulation of mtDNA heteroplasmy in all striated muscles of newborn mice by AAV9-mediated delivery of a mitochondria-targeted restriction endonuclease. Gene Ther. 2011, 10.1038/gt.2011.196.
80. Mancuso M., et al. Drugs and mitochondrial diseases: 40 queries and answers. Expert Opin. Pharmacother. 2012, 13:527-543.
81. Sadun A.A., et al. Effect of EPI-743 on the clinical course of the mitochondrial disease Leber hereditary optic neuropathy. Arch. Neurol. 2012, 69:331-338.
82. Klopstock T., et al. A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy. Brain 2011, 134:2677-2686.
83. Tachibana M., et al. Towards germline gene therapy of inherited mitochondrial diseases. Nature 2013, 493:627-631.
84. Paull D., et al. Nuclear genome transfer in human oocytes eliminates mitochondrial DNA variants. Nature 2013, 493:632-637.
85. Tachibana M., et al. Mitochondrial gene replacement in primate offspring and embryonic stem cells. Nature 2009, 461:367-372.
86. Craven L., et al. Pronuclear transfer in human embryos to prevent transmission of mitochondrial DNA disease. Nature 2010, 465:82-85.
87. Giordano C., et al. Oestrogens ameliorate mitochondrial dysfunction in Leber's hereditary optic neuropathy. Brain 2011, 134:220-234.
88. Zhang X., et al. Mouse model of optic neuropathy caused by mitochondrial complex I dysfunction. Neurosci. Lett. 2002, 326:97-100.
89. Przedborski S., et al. MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J. Bioenerg. Biomembr. 2004, 36:375-379.
90. Kruse S.E., et al. Mice with mitochondrial complex I deficiency develop a fatal encephalomyopathy. Cell Metab. 2008, 7:312-320.
91. Gispert S., et al. Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PLoS ONE 2009, 4:e5777.
92. Klein J.A., et al. The harlequin mouse mutation downregulates apoptosis-inducing factor. Nature 2002, 419:367-374.
93. Bénit P., et al. The variability of the harlequin mouse phenotype resembles that of human mitochondrial-complex I-deficiency syndromes. PLoS ONE 2008, 3:e3208.
94. Graziewicz M.A., et al. Structure-function defects of human mitochondrial DNA polymerase in autosomal dominant progressive external ophthalmoplegia. Nat. Struct. Mol. Biol. 2004, 11:770-776.
95. Han C., Someya S. Mouse models of age-related mitochondrial neurosensory hearing loss. Mol. Cell. Neurosci. 2013, 55:95-100.
96. Spelbrink J.N., et al. Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. Nat. Genet. 2001, 28:223-231.
97. Tyynismaa H., et al. Mutant mitochondrial helicase Twinkle causes multiple mtDNA deletions and a late-onset mitochondrial disease in mice. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:17687-17692.
98. Graham B.H., et al. A mouse model for mitochondrial myopathy and cardiomyopathy resulting from a deficiency in the heart/muscle isoform of the adenine nucleotide translocator. Nat. Genet. 1997, 16:226-234.
99. Fan W., et al. A mouse model of mitochondrial disease reveals germline selection against severe mtDNA mutations. Science 2008, 319:958-962.
100. Inoue K., et al. Generation of mice with mitochondrial dysfunction by introducing mouse mtDNA carrying a deletion into zygotes. Nat. Genet. 2000, 26:176-181.
101. Nakada K., et al. Accumulation of pathogenic DeltamtDNA induced deafness but not diabetic phenotypes in mito-mice. Biochem. Biophys. Res. Commun. 2004, 323:175-184.
102. Yokota M., et al. Generation of trans-mitochondrial mito-mice by the introduction of a pathogenic G13997A mtDNA from highly metastatic lung carcinoma cells. FEBS Lett. 2010, 584:3943-3948.
103. Raper S.E., et al. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum. Gene Ther. 2002, 13:163-175.
104. Jarraya B., et al. Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Sci. Transl. Med. 2009, 1:2ra4.
105. Quintana A., et al. Fatal breathing dysfunction in a mouse model of Leigh syndrome. J. Clin. Invest. 2012, 122:2359-2368.
106. Bouaita A., et al. Downregulation of apoptosis-inducing factor in Harlequin mice induces progressive and severe optic atrophy which is durably prevented by AAV2-AIF1 gene therapy. Brain 2012, 135:35-52.
107. Barber-Singh J., et al. Protective role of rAAV-NDI1, serotype 5, in an acute MPTP mouse Parkinson's model. Parkinsons Dis. 2010, 2011:438370.
108. Seo B.B., et al. In vivo complementation of complex I by the yeast Ndi1 enzyme. Possible application for treatment of Parkinson disease. J. Biol. Chem. 2006, 281:14250-14255.
109. Marella M., et al. Protection by the NDI1 gene against neurodegeneration in a rotenone rat model of Parkinson's disease. PLoS ONE 2008, 3:e1433.
110. Morais V.A., et al. Parkinson's disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function. EMBO Mol. Med. 2009, 1:99-111.